This Annual Report covers the SNO 2012 fiscal year, from July 1st, 2011 through June 30, 2012.
Dear Colleagues,

In this edition of our Annual Report, I am proud to be able to share with you some of the accomplishments at SNO over the past year. As we grow as an organization with over 1200 active members to date, each annual meeting becomes more impressive than the last and 2011’s meeting in Anaheim was no exception. There were a record number of attendees, we had a successful meeting carried out in collaboration with the American Association of Neurological Surgeons and Congress of Neurological Surgeons Joint Section on Tumors and we are indebted to Timothy Cloughesy and Michael Vogelbaum for jointly arranging a wonderful scientific program and Eric Chang, Arjun Sahgal, Jason Sheehan for leading the education day.

I am pleased to announce some exciting developments for the 2012 meeting in Washington, DC. There were 605 abstracts submitted and this year’s scientific program will be led by Antonio Chiocca, who deserves special thanks for organizing this critical component of the Society’s activities. The prior day (Thursday November 15) Balveen Kaur and Vinay Pduvalli have jointly coordinated an outstanding education day and Mike Glantz has put together an equally outstanding quality-of-life session to be held concurrently. This year a new clinical trials session, with a focus on biomarkers, has been added on Thursday afternoon, with leadership by Susan Chang.

In November 2013, the World Federation of Neuro-Oncology will meet in San Francisco, bringing together members of SNO, the Asian Society for Neuro-Oncology (ASNO), and the European Association of Neuro-Oncology (EANO) and we look forward to a dynamic meeting.

To continue its mission in promoting the advancement of neuro-oncology through education, SNO has developed several new initiatives aimed at increasing opportunities for junior investigators. These include travel scholarships reciprocated by EANO. This year, SNO members Justin Lathia and Sameer Agnihotri were awarded travel scholarships to the EANO meeting in Marseille, France. In addition, two junior EANO members received travel scholarships to attend and present at this year’s SNO meeting. The travel scholarship also serves as a mechanism to expand our collaborative relationships with sister societies and to foster the international relationships that are so enriching to the field.

In closing, a volunteer spirit and a willingness to contribute is what makes SNO thrive and I strongly encourage members to take an active role in SNO committees to bring new perspectives and to strengthen the group overall. In addition to shaping our future as a Society, the collaborations and friendships fostered as a result of participation in the Society remind us of why we have chosen this challenging field, they keep us focused on the discovery process for a better understanding of the biology of CNS neoplasia, and inspire us to learn how to better care for our patients.

Kenneth Aldape, MD
SNO President
Dear Members and Friends of SNO,

This Annual Report outlines the major accomplishments and successful projects undertaken by SNO from July 1, 2011 through June 31, 2012. As you will read in the pages that follow, 2012 was an exceptional year for our Society. It is certainly true that a constant factor in SNO’s success has been the dedication of its volunteer leadership. The Society is indebted to our out-going president, Frederick Lang, who led our Society with great skill, forging new partnerships with sister societies, reorganizing and revitalizing our committee structure and strengthening our international outreach efforts.

Our new president, Kenneth Aldape, takes the reins of a Society that has never been financially stronger or in a better position to achieve its mission. Today, we are in the enviable position of being able to make strategic investments back into the field of neuro-oncology – investments that are bolstering our educational offerings, adding more value to membership and strengthening our flagship publication, Neuro-Oncology.

This year, we have expanded our staff to support and manage the record-breaking attendance at our annual meeting. At the meeting itself, we have made significant and practical investments to improve our audio-visual support and the on-site experience of our members. During our 2012 Education Day, we will be providing attendees with an interactive audience response system to deliver content, collect data and evaluate learning. And, for the first time, SNO will be electronically capturing all of the educational and scientific sessions and making them available on-line to the entire neuro-oncology community after the meeting.

As part of our on-going efforts to advance the careers of the next generation of neuro-oncology professionals, SNO is supporting a number of initiatives for young investigators. At the annual meeting we will be hosting a special “roundtable” luncheon where young investigators will have the opportunity to interact with senior members of the Society. Immediately after the meeting, we have organized another career development opportunity where potential collaborators and mentors will gather for high-value exchanges that will form the basis of mutually beneficial professional relationships.

We continue to work with the European Association for Neuro-Oncology (EANO) to develop new interorganizational opportunities for professional exchange. There will be both EANO and ASNO organized sessions at our Washington meeting and reciprocal events have been planned for their events. And, through a competitive application process, young investigators from EANO and SNO were able to travel and present in each other’s 2012 meetings. These initiatives have proved so successful that we expect them to become regular features of our respective conferences in the future. This year we have also worked hard to draft a charter for the World Federation of Neuro-Oncology Societies which seeks to codify the organization of the quadrennial WFNO meeting, and ensures that all regional neuro-oncology societies are represented at an international level.

I am especially pleased that this year the SNO Board has established a new Public Service Award, and that Edward Shaw was selected as the inaugural recipient of this honor. As Dr. Shaw steps down as President of the SNO Foundation, we welcome Mark Gilbert to this important leadership position within the Society. As SNO continues its trajectory of growth, the Foundation will have an increasingly important role in facilitating communication between the SNO leadership and our non-profit and industry partners as we work together to advance the field.

A key factor in the success of any member-driven association is the collaborative synergy between the organization’s members and its administrative employees. I would therefore like to acknowledge the dedicated SNO staff – whether in-person, by telephone or email it is clearly evident that they routinely go “above and beyond” to meet the needs of our diverse membership.

It is indeed an exciting time for our Society. With a shared vision of success, our physician leadership and administrative staff are well positioned to grow our existing programs, establish new initiatives and increase educational opportunities to better serve our growing membership.

J. Charles Haynes, JD
SNO Executive Director
Dear Society for Neuro-Oncology Members and Supporters,

On behalf of the SNO Foundation, it is my great pleasure to present our Society’s 2012 Annual Report. Earlier this year, I was selected by the SNO Board of Directors to take on the role of President of the SNO Foundation after Dr. Edward Shaw stepped down from that position. It is a great honor to follow in Dr. Shaw’s footsteps; Dr. Shaw did an outstanding job in establishing the Foundation and creating a strong collaborative relationship with the Society for Neuro-Oncology. It is my task, along with the other members of the Foundation Executive Board, to carry his mission forward: to further expand the outreach and impact of the Foundation as we partner with SNO to advance treatment, research and education in the field.

The Foundation partners with SNO to support educational resources to better assist the clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumors in children and adults. The support of our corporate and foundation partners, as well as the generosity of our members, allows us to maintain the editorial office of Neuro-Oncology, the SNO administrative office, SNO’s international outreach efforts, as well as the costs associated with the SNO Annual Meeting, including travel scholarships, awards and initiatives for Young Investigators.

The Foundation clearly remains committed to the mission of SNO and I deeply thank those who have contributed to the Foundation. I look forward to meeting our supporters at the upcoming SNO meeting in Washington DC. At that meeting we are planning to launch a new program entitled “The Best of SNO”. This will take place on Sunday morning and attendance of this event will be by invitation. Summaries of the Education Day and the concurrent Quality of Life session will be provided, as well as highlights of the scientific sessions featuring this year’s award winning abstracts, and the Foundation supported satellite meeting.

The Foundation, as a major component of SNO, relies on the support of our corporate and foundation members as well as the individual society members. The Annual Meeting Support Program has facilitated growth in the Society’s premier education event. Those non-profit associations, foundations and societies, and corporate donors who support the Annual Meeting at the highest level with a multi-year commitment are members of the Partner’s Advisory Council, which has direct access to the SNO Board of Directors and Foundation Executive Board on a regular basis. The 2012 members of the Council include the American Brain Tumor Association, EMD Serono, Genentech, the National Brain Tumor Society, Merck, the Pediatric Brain Tumor Foundation and the Sontag Foundation.

As we look forward to the future, we anticipate major advances in our knowledge and ability to treat patients with brain tumors. The Foundation remains committed to supporting these efforts and to look for additional opportunities to expand our efforts. We ask that you continue your support and given the increasing excitement in the field and new discoveries, that you consider increasing your contributions. We have a common cause, a common avocation – find a cure for brain tumors.

Very truly yours,

Mark R. Gilbert, MD (Foundation President)
Mitchel S. Berger, MD
Susan M. Chang, MD
Victor A. Levin, MD
The 16th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology was held in conjunction with the AANS/CNS Section on Tumors on November 17–20, 2011, in Orange County, California. Timothy Cloughesy (SNO Scientific Program Chair) and Michael Vogelbaum (Section on Tumors Scientific Program Chair) collaborated to create a stimulating program which provided a comprehensive review of cutting-edge laboratory and clinical research in the field of neuro-oncology. The meeting afforded a distinctive environment for the multidisciplinary exchange of ideas among neuro-oncologists, medical oncologists, neurosurgeons, neuropathologists, radiation oncologists, neuroradiologists, pediatricians, laboratory scientists, nurses and other specialists involved in the research, diagnosis, care and treatment of patients with tumors of the central nervous system.

**Education Day**

The pre-meeting began on Thursday, November 17th with a well-timed and relevant program for the Education Day consisting of a morning session focused on Stereotactic Radiosurgery and concurrent afternoon sessions on Quality of Life / Symptom Management and a Clinical Trials Course for Young Investigators.

**SNO Annual Meeting**

The formal meeting launched on Friday November 18th with Sunrise Sessions on Viral Gene Therapy, Cancer Cell Metabolism, Surgery for Non-malignant Skull Base Tumors, and Advances in Neuro-Imaging. After the Official Meeting Welcome by Drs. Cloughesy and Vogelbaum, the Top Scoring Abstracts were awarded. The morning session was followed by an address from SNO president Dr. Frederick Lang, followed by the Victor Levin Award and Lecture by Kenneth Aldape of the MD Anderson Cancer Center.

A Young Investigators Luncheon Roundtable was held at noon on Friday at which trainees and early phase independent investigators participated in informal discussions with senior investigators at roundtables organized into eight different areas: Neurosurgery, Neurology, Adult Neuro-Oncology, Pediatric Neuro Oncology, Pathology, Allied Health Sciences, Basic Science, and Translational Science. The luncheon symposia were followed by afternoon concurrent sessions on Immunology and Cell Biology/Microenvironment, and subsequent concurrent sessions on Radiology and Preclinical Studies. After industry-sponsored satellite symposia, the evening opened for poster sessions, offering lively discussion and debate.

Saturday Sunrise Sessions featured meetings on Brain Cancer Cells of Origin, Intraoperative Surgical Adjuncts for Visualizing Tumor, Neurological Complications of Cancer Therapy in the CNS, and Diffuse Intrinsic Pontine Gliomas and other pediatric astrocytic tumors. These were followed by a plenary session presenting the Top Scoring Abstracts and the Keynote Lecture delivered by William Kaelin entitled *Using Cancer Genetics to Guide Drug Target Selection: Lessons From Gleevec and Beyond.* Another highlight of the morning session was the presentation of the SNO Lifetime Achievement Award to Jerome Poser. The first afternoon concurrent sessions were “-omics” and Pediatrics, and the subsequent afternoon concurrent sessions focused on Quality of Life and Surgical Therapies. The second poster session took place after the oral sessions concluded. Saturday evening, the SNO Banquet was held as the social highlight of the meeting.

Sunday, November 20th Sunrise Sessions included Molecular Pathology, Atypical and Malignant Meningioma, and Immunobiology. These were followed by a plenary session on Medical and Neuro-Oncology with a Clinical Trials update prior to the meeting adjournment.
Kenneth Aldape receives the Victor Levin Award from 2011 SNO President, Frederick Lang

The Victor Levin Award and Lecture in Neuro-Oncology Research

The Victor Levin Award and Lecture is named in honor of SNO’s founder, Dr. Victor Levin. Established in 2010, this award is given each year to an individual with a career commitment to neuro-oncology who has demonstrated leadership and, through scientific innovation, has made extraordinary achievements in neuro-oncology research. The award is open to all SNO members, from all disciplines and in any stage of their professional career.

The Society for Neuro-Oncology was pleased to present this award to Kenneth Aldape at our 2011 annual meeting where he delivered a talk entitled Biomarker-based Approaches to Classify Brain Tumors. In addition to his many scientific accomplishments, Dr. Aldape has served in a number of leadership positions within SNO, and at the time of the award was voted by the membership to serve as the president-elect of the Society.

Abstract Award Winners

Kenneth D. Aldape, MD
Award for Excellence in Translational Research
Clinical utility of G-CIMP and IDH1 status as dual prognostic markers in glioblastoma

Terri Armstrong, PhD
Award for Excellence in Quality of Life Research, Supported by the Sontag Foundation
Clinical utility of Quality of Life (QOL) and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525

Kristine Dziurzynski, MD
Award for Excellence in Basic Research, Supported by Genentech
Cytomegalovirus subverts the monocyte lineage to become glioma propagating

Frank Furnari, PhD
Award for Excellence in Translational Research, Supported by EMD Serono
PTEN phosphorylation by fibroblast growth factor receptors and SRC mediates resistance to epidermal growth factor receptor inhibitors in glioma

Mark R. Gilbert, MD
Award for Excellence in Clinical Research, Supported by the National Brain Tumor Society
RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM)

David A. Largaespada, PhD
Award for Excellence in Pediatric Basic Research, Supported by the Pediatric Brain Tumor Foundation
Transposoncogenetics implicates a novel RhoGAP and other genetic drivers of primitive neuroectodermal tumors

Justin D. Lathia, PhD
Award for Excellence in Basic Research, Supported by the American Brain Tumor Association
Seeing is believing: Utilization of intravital microscopy to evaluate tumor growth and therapeutic response of transplanted human glioma stem cells

Pablo A. Valdes, PhD
Award for Excellence in Translational Research, Supported by Merck, Inc.
Combined fluorescence and reflectance spectroscopy for in vivo quantification of cancer biomarkers in low- and high-grade glioma surgery
In 2012 the Society for Neuro-Oncology was pleased to announce that Dr. Rahul Krishnatry of India was selected as the third SNO International Outreach Research Fellow. This fellowship is made possible through a generous grant from the American Brain Tumor Association and EMD Serono.

The review committee was impressed with Dr. Krishnatry’s application and gave his submission uniformly high marks. Dr. Krishnatry is a promising clinician/scientist who has distinguished himself in his home country. While he has received excellent training at Tata Memorial Hospital in Mumbai, pediatric neuro-oncology is still in its infancy in India, and the committee felt that this Fellowship would provide him with the necessary expertise to make a significant difference upon his return to India. Tata is the largest hospital in India seeing 40,000 new cancer patients per year. Consequently, through this Fellowship, Dr. Krishnatry has a tremendous opportunity to take a leadership role in advancing pediatric neuro-oncology both at Tata and within the Indian Society for Neuro-Oncology of which he is an active member.

The Hospital for Sick Children in Toronto has agreed to host Dr. Krishnatry for the one-year Fellowship period. While in Canada, he will be under the mentorship of Eric Bouffet who has an established track record of supporting outreach programs in developing countries. Dr. Krishnatry has been invited to be a guest of SNO at the 2013 World Federation of Neuro-Oncology Meeting that will take place in San Francisco, in November, 2013, where he will have the opportunity to update our membership on his progress in Toronto.

SNO International Outreach Research Fellowships

**2009 – 2010**
Yi Lin (China)
Mentor: Jay-Jiguang Zhu
UT Houston/Memorial Hermann at Texas Medical Center

**2011 – 2012**
Jun-ping Zhang (China)
Mentor: Patrick Wen
Dana–Farber Cancer Institute

**2013 – 2014**
Rahul Krishnatry (India)
Mentor: Eric Bouffet
The Hospital for Sick Children
2012 Travel Scholarship Recipients

Asha Arjunan  
India

James Ayokunle Balogun  
Nigeria

Kamal Eldein Hamed Mohamed  
Sudan

Hamoud Hodeish Yahya Al-hussaini  
Yemen

Damayanthi Pieris  
Sri Lanka

Rashim Kataria  
India

Keith R. Britton  
Panama

Ana Veronica Giron Santizo  
Guatemala

Navchaa Gombodorj  
Mongolia

Rosario Marissa B. Lukban  
Philippines

Edin Hajdarapasic  
Bosnia and Herzegovina

Travel Scholarships

to the SNO annual meeting to physicians from the following countries:

Algeria  Namibia
Bosnia and Herzegovina  Nepal
China  Nigeria
Columbia  Panama
Cuba  Pakistan
Egypt  Philippines
Georgia  Russia
Guatemala  Serbia
India  Sudan
Indonesia  Thailand
Kyrgyzstan  Venezuela
Mauritanie  Yemen
Mongolia

SNO Creates New Public Service Award

This year the SNO Board of Directors introduced a new Public Service Award to recognize a meritorious individual who has increased public awareness of brain cancer, advanced advocacy, promoted legislative action, or has otherwise supported the mission of the Society for Neuro-Oncology. Candidates do not have to be a SNO member to be eligible for this award, and may be a healthcare provider, administrator, patient, family member.

The SNO Board was unanimous in agreeing that Edward Shaw should be selected as the inaugural recipient of this award. In 2005, while serving as SNO President, Dr. Shaw initiated a strategic planning process which led to the establishment of the SNO Foundation, ensuring the long-term security and financial stability of the Society. His work to strengthen SNO’s administrative infrastructure allowed the Society to evolve into a mature organization and a dynamic force in neuro-oncology. Dr. Shaw will receive the inaugural SNO Public Service Award during the opening plenary session of the 2012 annual SNO meeting in Washington, DC.

Edward Shaw will be the inaugural recipient of the SNO Public Service Award.
Neuro-Oncology, the official journal of the Society for Neuro-Oncology, has experienced continued growth and success over the past year. The journal’s editors and editorial staff members have been carefully expanding and improving the journal to help SNO meet its goal of advancing multidisciplinary research and education in neuro-oncology.

Higher Impact Factor Reflects Sustained Quality
Neuro-Oncology’s ongoing commitment to quality helped it earn an impact factor of 5.723 for 2011 (Figure 1), this score is particularly exciting because it is the first to reflect the journal’s move to monthly publication in 2010. It also demonstrates the journal’s ongoing commitment to publishing only the most significant neuro-oncology research. Of note, the journal’s only direct competitor received a score of 3.214. Neuro-Oncology is now ranked 22 of 194 oncology journals, placing it alongside journals such as Neoplasia, Carcinogenesis, and Radiotherapy and Oncology, and 15 of 191 clinical neurology journals. Both of these rankings are higher than were those in 2010.

Increase in Submitted and Published Articles
The journal is delighted to report a substantial increase in the number of new submissions in 2012. Our editors—Editor-in-Chief W. K. Alfred Yung, SNO Executive Editor C. David James, JSNO Executive Editor Ryo Nishikawa, and EANO Executive Editor Michael Weller—will have acted on a projected 888 new and revised manuscripts (669 new and 219 revised) by the end of 2012 (Table 1). This total is a substantial increase over those of 2011 (671) and 2010 (564), when the journal moved to monthly publication. From January 1 through September 30, 113 papers were accepted for publication. The journal's acceptance rate has been declining, demonstrating a continued dedication to publishing only the most significant research, even as the number of submissions increase.

Through the September issue, Neuro-Oncology published 119 articles in 1170 pages (versus 102 in 1043 pages in 2011), demonstrating continued growth despite an increase in frequency in 2010. The journal also published meeting supplements for the International Symposium on Pediatric Neuro-Oncology, British Neuro-Oncology Society, European Association for Neuro-Oncology, and SNO. In addition, it published an applied article supplement for SNO and an annual report for the Central Brain Tumor Registry for the United States. An impressive 655 abstracts were submitted for the SNO annual conference.

As of September 30, Neuro-Oncology acted on manuscripts from 37 countries. The journal received more submissions from Asia in 2012 than it did in 2011 (25% versus 19%). Approximately half of all papers accepted to Neuro-Oncology are from the United States and Canada.

Figure 1. Neuro-Oncology’s impact factors, 2002–2011. The impact factor, published annually by Thomson Scientific in the Journal Citation Reports, is determined using article citation rates and is used to measure journal quality.
Neuro-Oncology is indebted to the tireless members of its editorial board (whose names appear in every issue of the journal) and its numerous peer and statistical reviewers, all of whom have helped the journal along its path to success. Listed below are those reviewers who had agreed to conduct manuscript reviews as of September 30. The staff apologizes for any inadvertent omissions.

### Special Publications

As reported in the June 2012 issue of *Neuro-Oncology*, a substantial percentage of the cell lines used in medical research are contaminated or misidentified. To help address this issue, beginning in volume 15, the journal will begin requiring a statement of cell line validation. Authors should describe the validation used for the reported cell lines or briefly explain why this step was not needed. The journal encourages all of its authors, reviewers, and board members to be vigilant about this issue in support of *Neuro-Oncology*’s continued commitment to scientific integrity.

The editors and editorial staff members of *Neuro-Oncology* hope to continue providing in-depth analyses of significant topics in the field while remaining sensitive to readers’ needs.

### Peer & Statistical Reviewers

*Neuro-Oncology* is indebted to the tireless members of its editorial board (whose names appear in every issue of the journal) and its numerous peer and statistical reviewers, all of whom have helped the journal along its path to success. Listed below are those reviewers who had agreed to conduct manuscript reviews as of September 30. The staff apologizes for any inadvertent omissions.

<table>
<thead>
<tr>
<th>Type of manuscript</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012 through Sept. 30, 2012 (projected end of year)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New</td>
<td>455</td>
<td>411</td>
<td>454</td>
<td>501 (669)</td>
</tr>
<tr>
<td>Revised</td>
<td>121</td>
<td>153</td>
<td>217</td>
<td>165 (219)</td>
</tr>
</tbody>
</table>

Table 1. Submissions of new and revised manuscripts to *Neuro-Oncology*

---

Roger Abounader  
Manish Aghi  
Yukinori Akiyama  
Francis Ali-Osman  
James Angelastro  
Terri Armstrong  
Ute Bartels  
Elizabeth Beierle  
Michael Berens  
Jaclyn Biegel  
Stefan Blüml  
Wolfgang Bohn  
Eric Bouffet  
Michael Brada  
Cameron Brennan  
Alain Charest  
Nicholas Butowski  
J. Gregory Cairncross  
Robert Castellino  
Alain Charest  
Pin-Yuan Chen  
Jennifer Clarke  
Timothy Cloughesy  
Charles Cobb  
Andrew Kobel  
Howard Colman  
Sidney Croul  
Johannes Czernin  
Faith Davis  
John de Groot  
Waldemar Debinski  
Steven Devleeschouwer  
Francois Doz  
François Ducray  
Anat Erdreich-Epstein  
Bradley Erickson  
Christian Farrar  
Andres Ferreri  
Graziella Filippini  
Paul Fisher  
Nicholas Foreman  
John Forsayeth  
Peter Forsyth  
Maryam Fouladi  
Juan Fueyo-Margareto  
Takamitsu Fujimaki  
Mitsugu Fujita  
Felice Giangaspero  
Mark Gilbert  
Candela Garcia-Manzano  
Gerald Grant  
Corinne Griguer  
Morris Groves  
Eric Guedj  
Nalin Gupta  
Daphne Haas-Kogan  
C. Oliver Hanemann  
Chunhai (Charlie) Hao  
Elke Hattingen  
Cynthia Hawkins  
Christel Herold-Mende  
Ulrich Herrlinger  
Kenneth Hess  
Yuichi Hirose  
Katherine Hoadley  
Khê Hoang-Xuan  
Suyun Huang  
Peter Inskeep  
Yasuhiro Iwasada  
Fabio Iwamoto  
Nada Jabado  
Andrew Jacobs  
Rajan Jain  
Mark Johnson  
Dieter Gabriel  
Bernd Kaina  
Michel Kalamarides  
Andrew Kaye  
Santosh Kesari  
Raja Khan  
Chifumi Kitakami  
Peter Krauseneck  
Johan Kros  
Asok Kumar  
Nadia Laack  
Anand Lagoo  
Florence Laigle-Donadey  
Katrin Lamus  
Joseph Landolfi  
Heiner Lanfermann  
Frederick Lang  
Peder Larson  
Alexander Lassman  
Justin Lathia  
Florence Lefrant  
Laurent Lemaire  
Maciej Lesniak  
Xiao-Nan Li  
Maria Beatriz Lopes  
Lorenzo Magrassi  
Keishi Makino  
Warren Mason  
Tracy McKnight  
Alex McMillan  
Duane Mitchell  
Shin-Ichi Miyake  
Sabine Mueller  
Akitaka Muka  
Jean Nakamura  
Yoko Nakasu  
Sarah Nelson  
Edward Neuwelt  
Theodore Nicolaides  
Andrew Norden  
Brian O'Neill  
Hidehiko Okada  
John Park  
Giorgio Perilongo  
Anders Persson  
Joanna Phillips  
Karl Plate  
Michael Platten  
Whitney Pope  
Hans Poulsen  
Robert Prins  
Alfredo Quinones-Hinojosa  
Samuel Rabkin  
Jeffrey Raizer  
Zvi Ram  
Sandra Rempel  
Lucy Rorke-Adams  
James Rubenstein  
Deepa Sampath  
Raymond Sawaya  
Kathleen Schmaida  
S. Clifford Schold  
Judith Schwartzbaum  
Andrew Sloan  
Robert Sobol  
Kazuhiko Sugiyama  
Erik Sulman  
Ghazaleh Tabatabai  
Uri Tabori  
Jun Takahashi  
Hideo Takeshima  
Rheal Towner  
Keisuke Ueki  
Roland Ulrich  
Radna Vdlamudi  
Mariano Viapiano  
Samuel Weiss  
Theresa Whiteside  
Xifeng Wu  
Hai Yan  
Takayuki Yanagisawa  
Isaac Yang  
Seiichi Yoshida  
David Zaggag  
Xiang Zhang
The following financial highlights are prepared by management of Society for NeuroOncology for the fiscal year ended June 30, 2011 and are intended for this Annual Report, only. The financial information is in the process of being audited by an independent accounting firm. Once the audit is complete, the financial statements and Independent Auditor’s Report will be posted at www.Soc-Neuro-Onc.org.

### Statement of Financial Position highlights, as of June 30, 2011

<table>
<thead>
<tr>
<th></th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$ 833,000</td>
</tr>
<tr>
<td>Investments</td>
<td>703,000</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>44,000</td>
</tr>
<tr>
<td>Endowment assets</td>
<td>156,000</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$ 1,736,000</strong></td>
</tr>
<tr>
<td>Liabilities</td>
<td>$ 246,000</td>
</tr>
<tr>
<td>Net assets</td>
<td>1,490,000</td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>$ 1,736,000</strong></td>
</tr>
</tbody>
</table>

### Statement of Activities highlights, for the fiscal year ended June 30, 2011

<table>
<thead>
<tr>
<th></th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues and other support</td>
<td>$ 1,782,000</td>
</tr>
<tr>
<td>Total program and supporting service expenses</td>
<td>1,284,000</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td><strong>$ 498,000</strong></td>
</tr>
</tbody>
</table>
The following financial highlights are prepared by management of Society for NeuroOncology for the fiscal year ended June 30, 2012 and are intended for this Annual Report, only. The financial information is in the process of being audited by an independent accounting firm. Once the audit is complete, the financial statements and Independent Auditor’s Report will be posted at www.Soc-Neuro-Onc.org.

### Statement of Financial Position highlights, as of June 30, 2012

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,240,000</td>
</tr>
<tr>
<td>Investments</td>
<td>676,000</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>45,000</td>
</tr>
<tr>
<td>Endowment assets</td>
<td>156,000</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$2,117,000</strong></td>
</tr>
<tr>
<td>Liabilities</td>
<td>$196,000</td>
</tr>
<tr>
<td>Net assets</td>
<td>1,921,000</td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>$2,117,000</strong></td>
</tr>
</tbody>
</table>

### Statement of Activities highlights, for the fiscal year ended June 30, 2012

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues and other support</td>
<td>$1,821,000</td>
</tr>
<tr>
<td>Total program and supporting service expenses</td>
<td>1,388,000</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td><strong>$433,000</strong></td>
</tr>
</tbody>
</table>
ADMINISTRATIVE STAFF

Executive Director
J. Charles (Chas) Haynes, J.D.

Chief Administrative Officer
Jan Esenwein

Membership Manager
Linda Greer

Administrative Coordinator
Megan Bell

Communications Coordinator
Kristin Odom
OFFICERS, BOARD OF DIRECTORS AND COMMITTEES

President
Kenneth Aldape, MD

Vice President
Michael Vogelbaum, MD, PhD

Secretary-Treasurer
E. Antonio Chiocca, MD, PhD

Board of Directors
Eric Bouffet, MD
Sherry Fox, PhD
Mary Lovely, PhD
Andrew Parsa, MD
David Peereboom, MD
Russell Pieper, PhD
David Reardon, MD
Jann Sarkaria, MD
Michael Taylor, MD, PhD

Past President
Frederick Lang, MD

Foundation Board
Mark R. Gilbert, MD (President)
Victor A. Levin, MD (SNO Founder)
Mitchel S. Berger, MD
Susan Chang, MD

Journal Editor in Chief
W. K. Alfred Yung, MD

Journal Executive Editor (SNO)
C. David James, PhD

SNO STANDING COMMITTEES

The Audit Committee shall consist of the Chair, Vice President of the Society and the Secretary-Treasurer. The committee shall have the responsibility of overseeing annual internal audit of the Society’s financial affairs, and conveying the audit to the President and the Board, who may approve review of the audit by external committees as needed. The committee shall also advise and make recommendations to the Board of Directors based on findings of such audits. The Audit Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Gene Barnett

The Awards Committee shall consist of the Chair, the Scientific Program Chair and other members who shall develop criteria for all SNO meeting awards, annually review meeting award candidates, and forward to the Board a list of awards and award recipients to be honored at the Annual Meeting. The Awards Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: David Eisenstat

The Bylaws Committee shall consist of the Chair, the Secretary/Treasurer (ex officio) and two other members who shall review the Bylaws annually and make recommendations for revision as necessary. Members of this committee shall review any proposed changes and advise the Board of Directors on proposed revisions. The Bylaws Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Thomas Mikkelsen

The Communications Committee shall consist of the Chair, the Secretary/Treasurer (ex officio) and other members who shall be responsible for the news section of the Society’s official journal and the Society’s newsletter, and will have the responsibility of advising the Board of Directors on the Society’s internal and external communications. The Communications Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Nicholas Butowski

The Future Sites Committee shall consist of the Chair, a previous Chair of the Annual Meeting Committee and two other members who shall review potential sites and hotel proposals for future meetings, evaluating size and appropriateness of meeting space, availability and quality of sleeping rooms, proposed room rates, and recommends to the Board the most appropriate venue. The Future Sites Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Co-Chairs: Jonathan Knisely and Mark Gilbert
The International Outreach Committee shall consist of the Chair and other representative international members recommended by the Chair or President, as approved by the Board of Directors. The committee shall have the responsibility of advising and making recommendations to the Board of Directors on international affairs, promoting international membership, and shall develop the criteria and review candidates for SNO international outreach travel grants and fellowships. The International Outreach Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Eric Bouffet

The Annual Meeting Committee shall consist of a Scientific Program Chair, Education Day Chair, the immediate past Chairs of the Annual Meeting Committee and other members representing each of the SNO specialty areas who shall supervise and coordinate all aspects of the next SNO Scientific Meeting and Education Day. The Meeting Committee members shall serve a one-year term and such term may be renewable at the discretion of the President.

Chair: Antonio Chiocca

The Membership Committee shall consist of the Chair and four members who shall make recommendations to the Board of Directors concerning efforts to promote and increase membership in Society. They shall also review and vote on all applicants for membership and shall evaluate a member's professional conduct as requested by a majority of the Board of Directors. The Membership Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Gregory Foltz

The Website Committee shall consist of the Chair and other members who shall have the responsibility of coordinating and overseeing the Society's official website. The Website Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Erik Sulman

The Young Investigators Committee shall consist of the Chair and other members who shall have the responsibility of advising the Board of Directors on issues pertaining to graduate students, residents, fellows and members within the first five years of their initial clinical or academic appointment. The Young Investigators Committee shall also have the responsibility of coordinating the SNO Grant Review initiative. The Young Investigators Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Jason Huse
## SNO SUPPORTERS

**Through 2012 Fiscal Year Ending June 31, 2012**

### Platinum Level
- American Brain Tumor Association
- EMD Serono
- Genentech
- Merck
- National Brain Tumor Society
- Pediatric Brain Tumor Foundation
- Sontag Foundation

### Benefactors
- Brainlab
- CERN Foundation
- Novocure

### Supporters
- Brain Tumour Foundation of Canada
- Eisai
- Elekta
- Northwest Biotherapeutics
- Stryker

### International Outreach
- American Brain Tumor Association
- EMD Serono
- Eric Bouffet, MD
- Children's Brain Tumor Foundation
- Ali Choucair, MD
- Jonathan Finlay, MD
- Victor Levin Founders Society

### Neuro-Tumor Club Meeting
- Castle Biosciences
- Genentech
- Merck
- National Brain Tumor Society

### Individual Donations
- Joyce Davis
  *in memory of Jill Holtz*
- Jacqueline Prescott
  *in memory of Jill Holtz*
- Randy Gillman
  *in memory of Jill Holtz*

- Michael & Penny Sherman
  *in memory of Jill Holtz*
- Gwen & Bob Kahl
  *in memory of Dr. Gerald Rakotz*
- Mary Dwyer
  *in memory of Samuel Perkins*
- Janice Kay
  *in memory of Herbert Kay*
- Victor Levin, MD
- David Peereboom, MD

### Exhibitors
- American Brain Tumor Association
- Brain Tumour Foundation of Canada
- Brainlab
- Castle Biosciences Inc.
- CERN Foundation
- CombiMatrix Diagnostics
- Diplomat Specialty Pharmacy
- Eisai
- Elekta
- EMD Serono, Inc.
- Genentech
- International Brain Tumour Alliance
- LabCorp
- MERCK
- Monteris Medical
- National Brain Tumor Society
- Northwest Biotherapeutics
- Novartis
- NovoCure
- Oxford University Press
- Pediatric Brain Tumor Foundation
- Sigma-Tau Pharmaceuticals, Inc.
- Stryker
- Tocagen
**Mission**

SNO fosters multidisciplinary neuro-oncology research and education to improve patient outcomes.

**Vision**

SNO is the pre-eminent multidisciplinary society involved in state-of-the-art neuro-oncology research, education, and patient care.

---

**SNO Members**

- Neurosurgery 18%
- Basic Science 9%
- Neuro-oncology 26%
- Radiation Oncology 8%
- Other:
  - Radiology 1%
  - Psychology 1%
  - Pharmacology 1%
  - Epidemiology 1%
  - Statistics 1%
  - Public Health 1%
  - Nursing 2%
  - Pediatric Oncology 4%
  - Pathology 5%
- Medical Oncology 5%
- Associate Trainee 22%